Fibroscan Study in HCC

The Chinese University of Hong Kong

Status: Active, not recruiting

Conditions: Child's A to C Cirrhosis; Confirmed Diagnosis of Hepatocellular Carcinoma; Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery

Treatments: Other: Fibroscan

Study type: Interventional

Funder types: Other

Identifiers

NCT01796145

HCC033

Details and patient eligibility

About

In patients with HCC undergoing therapy 1. We aim to determine the prognostic significance of liver stiffness in patients with HCC 2. We aim to determine the rate and severity of complications of treatment and its association with liver stiffness in patients with HCC

Enrollment: 207 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of HCC

• Patients who are scheduled to undergo therapy, either TACE systemic therapy or surgery

  1. For TACE cohort, patients undergoing first cycle TACE are eligible.
  2. For systemic therapy cohort, patients undergoing first-line systemic therapy are eligible.
  3. For surgery cohort, patient undergoing surgery are eligible.

• Prior surgery or loco-ablative therapy (e.g. Radiofrequency ablation, microwave, percutaneous ethanol injection) is allowed

• Child's A to Child's C liver function

Exclusion criteria

• ECOG performance status > 2
• Poorly controlled ascites

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

207 participants in 3 patient groups

TACE

Experimental group

Treatment:

Other: Fibroscan

Systemic Therapy

Experimental group

Treatment:

Other: Fibroscan

Surgery

Experimental group

Treatment:

Other: Fibroscan